SG11202104103XA - Methods for characterizing disulfide bonds - Google Patents
Methods for characterizing disulfide bondsInfo
- Publication number
- SG11202104103XA SG11202104103XA SG11202104103XA SG11202104103XA SG11202104103XA SG 11202104103X A SG11202104103X A SG 11202104103XA SG 11202104103X A SG11202104103X A SG 11202104103XA SG 11202104103X A SG11202104103X A SG 11202104103XA SG 11202104103X A SG11202104103X A SG 11202104103XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- disulfide bonds
- characterizing
- characterizing disulfide
- bonds
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792994P | 2019-01-16 | 2019-01-16 | |
| PCT/US2020/013907 WO2020150491A1 (en) | 2019-01-16 | 2020-01-16 | Methods for characterizing disulfide bonds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104103XA true SG11202104103XA (en) | 2021-05-28 |
Family
ID=69570836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104237YA SG11202104237YA (en) | 2019-01-16 | 2020-01-16 | Methods for identifying free thiols in proteins |
| SG11202104103XA SG11202104103XA (en) | 2019-01-16 | 2020-01-16 | Methods for characterizing disulfide bonds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104237YA SG11202104237YA (en) | 2019-01-16 | 2020-01-16 | Methods for identifying free thiols in proteins |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11674968B2 (en) |
| EP (3) | EP3857236A1 (en) |
| JP (2) | JP2022517720A (en) |
| KR (2) | KR20210114926A (en) |
| CN (3) | CN113272651B (en) |
| AU (2) | AU2020208396A1 (en) |
| BR (1) | BR112021009543A2 (en) |
| CA (2) | CA3116735A1 (en) |
| DK (1) | DK3857237T3 (en) |
| EA (2) | EA202191841A1 (en) |
| ES (1) | ES2942024T3 (en) |
| FI (1) | FI3857237T3 (en) |
| HU (1) | HUE061783T2 (en) |
| IL (2) | IL284473A (en) |
| MX (2) | MX2021008589A (en) |
| PL (1) | PL3857237T3 (en) |
| SG (2) | SG11202104237YA (en) |
| WO (2) | WO2020150492A1 (en) |
| ZA (2) | ZA202102546B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202429A1 (en) * | 2020-12-20 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Methods for identification of scrambled disulfides in biomolecules |
| US20240060988A1 (en) * | 2021-02-25 | 2024-02-22 | Dr. Reddy’S Laboratories Limited | Thiol variants and analytical methods thereof |
| CN113189254B (en) * | 2021-05-08 | 2021-11-16 | 北京工商大学 | Determination method based on volatile thiol compounds in white spirit |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| TW574597B (en) | 2002-03-08 | 2004-02-01 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| PT2374818E (en) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
| PT2975051T (en) | 2009-06-26 | 2021-05-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
| EP2579897A1 (en) * | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
| AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
| PL2624865T3 (en) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
| CA2820630A1 (en) * | 2010-12-09 | 2012-06-14 | Bayer Healthcare Llc | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| JO3412B1 (en) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | Anti-angptl3 antibodies and uses thereof |
| HUE038570T2 (en) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| US9402898B2 (en) | 2012-01-23 | 2016-08-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
| US9835629B2 (en) | 2012-05-18 | 2017-12-05 | Pierce Biotechnology, Inc. | Methods and reagents for biomolecule labeling, enrichment and gentle elution |
| TW201843172A (en) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
| AR092098A1 (en) | 2012-08-13 | 2015-03-25 | Regeneron Pharma | ANTI-PCSK9 ANTIBODIES WITH PHASE DEPENDENT UNION CHARACTERISTICS |
| JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
| JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
| JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
| TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
| JP6404314B2 (en) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | IL-33 antagonists and uses thereof |
| TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| WO2015138460A1 (en) | 2014-03-11 | 2015-09-17 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibodies and uses thereof |
| TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
| MA51519A (en) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | HUMANIZED C5 AND C3 ANIMALS |
| JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
| US10690676B2 (en) | 2014-07-29 | 2020-06-23 | Mayo Roundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by LC-MS/MS |
| WO2016044337A1 (en) | 2014-09-16 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
| CN108627647B (en) * | 2017-03-24 | 2020-06-19 | 四川大学 | Detection and quantification method of post-translational modification proteomics |
| CN109142561A (en) * | 2018-07-17 | 2019-01-04 | 上海师范大学 | The method and its application of simultaneous quantitative protein abundance and cysteine oxidation level |
-
2020
- 2020-01-16 AU AU2020208396A patent/AU2020208396A1/en active Pending
- 2020-01-16 JP JP2021532314A patent/JP2022517720A/en not_active Withdrawn
- 2020-01-16 ES ES20706372T patent/ES2942024T3/en active Active
- 2020-01-16 AU AU2020208395A patent/AU2020208395A1/en active Pending
- 2020-01-16 PL PL20706372.8T patent/PL3857237T3/en unknown
- 2020-01-16 JP JP2021532315A patent/JP2022517721A/en active Pending
- 2020-01-16 CN CN202080006686.9A patent/CN113272651B/en active Active
- 2020-01-16 CA CA3116735A patent/CA3116735A1/en active Pending
- 2020-01-16 WO PCT/US2020/013910 patent/WO2020150492A1/en unknown
- 2020-01-16 US US16/745,020 patent/US11674968B2/en active Active
- 2020-01-16 MX MX2021008589A patent/MX2021008589A/en unknown
- 2020-01-16 US US16/745,006 patent/US11579150B2/en active Active
- 2020-01-16 EA EA202191841A patent/EA202191841A1/en unknown
- 2020-01-16 SG SG11202104237YA patent/SG11202104237YA/en unknown
- 2020-01-16 EP EP20704983.4A patent/EP3857236A1/en active Pending
- 2020-01-16 KR KR1020217016160A patent/KR20210114926A/en active Search and Examination
- 2020-01-16 CN CN202080006660.4A patent/CN113272650A/en active Pending
- 2020-01-16 KR KR1020217016167A patent/KR20210114927A/en not_active Application Discontinuation
- 2020-01-16 SG SG11202104103XA patent/SG11202104103XA/en unknown
- 2020-01-16 FI FIEP20706372.8T patent/FI3857237T3/en active
- 2020-01-16 HU HUE20706372A patent/HUE061783T2/en unknown
- 2020-01-16 CN CN202310621246.XA patent/CN117110492A/en active Pending
- 2020-01-16 EP EP23150144.6A patent/EP4220173A3/en active Pending
- 2020-01-16 DK DK20706372.8T patent/DK3857237T3/en active
- 2020-01-16 MX MX2021008590A patent/MX2021008590A/en unknown
- 2020-01-16 CA CA3116732A patent/CA3116732A1/en active Pending
- 2020-01-16 EA EA202191699A patent/EA202191699A1/en unknown
- 2020-01-16 WO PCT/US2020/013907 patent/WO2020150491A1/en unknown
- 2020-01-16 EP EP20706372.8A patent/EP3857237B1/en active Active
- 2020-01-16 BR BR112021009543-8A patent/BR112021009543A2/en unknown
-
2021
- 2021-04-16 ZA ZA2021/02546A patent/ZA202102546B/en unknown
- 2021-04-16 ZA ZA2021/02547A patent/ZA202102547B/en unknown
- 2021-06-29 IL IL284473A patent/IL284473A/en unknown
- 2021-06-29 IL IL284471A patent/IL284471A/en unknown
-
2023
- 2023-01-13 US US18/154,401 patent/US20230280354A1/en active Pending
- 2023-05-02 US US18/142,193 patent/US20230273216A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201907244D0 (en) | Method | |
| IL284473A (en) | Methods for characterizing disulfide bonds | |
| GB201911286D0 (en) | Method | |
| EP3643265C0 (en) | Loose mode for robot | |
| GB201910759D0 (en) | Method | |
| GB201907882D0 (en) | Methods | |
| SG11202010335WA (en) | Techniques for performing secure operations | |
| GB201900940D0 (en) | Method | |
| GB201913716D0 (en) | Methods | |
| GB201906705D0 (en) | Methods | |
| GB201907782D0 (en) | Method | |
| GB201903909D0 (en) | Methods | |
| IL269414A (en) | Rapar for safetyin taneis | |
| EP4058339A4 (en) | Extension gate for trolley | |
| GB201913062D0 (en) | Jigs | |
| EP4038198C0 (en) | Method | |
| GB201907326D0 (en) | Arm assist | |
| GB201911910D0 (en) | Methods | |
| GB201909704D0 (en) | Methods | |
| GB201908348D0 (en) | Methods | |
| GB201907157D0 (en) | Methods | |
| GB201913970D0 (en) | Method | |
| GB201912475D0 (en) | Method | |
| GB201912473D0 (en) | Method | |
| GB201910839D0 (en) | Method |